ity and validity of the modified Decisional Conflict Scale for use in decisions associated with genetic testing for HBOC. b Methods: This cross-sectional cohort study, recruited women who pursued genetic testing for HBOC in two genetic risk assessment clinics affiliated with a large comprehensive cancer center and one of their female relatives who did not pursue testing. The final sample consisted of 342 women who completed all 16 items of the Decisional Conflict Scale. The psychometric properties of the scale were assessed using tests of reliability and validity, including face, content, construct, contrast, convergent, divergent, and predictive validity. b Results: Factor analysis using principal axis factoring with oblimin rotation elicited a three-factor structure: (a) Lack of Knowledge About the Decision (! = .97), (b) Lack of Autonomy in Decision Making (! = .94), and (c) Lack of Confidence in Decision Making (! = .87). These factors explained 82% of the variance in decisional conflict about genetic testing. Cronbach's alpha coefficient was .96. b Discussion: The instrument is an important tool for researchers and healthcare providers working with women at risk for HBOC who are deciding whether genetic testing is the right choice for them. b Key Words: Decisional Conflict Scale & hereditary breast and ovarian cancer (HBOC) & psychometric testing H ereditary breast and ovarian cancer (HBOC) syndrome is the collective term used to describe ge-netic susceptibility to breast and ovarian cancer (American Cancer Society [ACS], 2011) . Mutations in the Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) genes, hereafter referred to as BRCA1/2, account for the majority of these cases. Mutation carriers have significantly higher risk for developing breast cancer compared with the general population (55%Y85% vs. 12%) and for developing ovarian cancer (20%Y60% vs. 1.5%). Genetic testing for HBOC provides individuals the opportunity to determine their cancer risk and make decisions to potentially reduce the occurrence of the syndrome. Patients already diagnosed with breast or ovarian cancer benefit from knowing their mutation status before making surgical decisions, whereas cancer-free individuals might use this information to make informed life decisions (e.g., reproduction) and take proactive steps toward risk management (i.e., increased surveillance, chemoprevention, and risk-reducing surgery; Eisinger et al., 2001; Finch et al., 2006; Metcalfe et al., 2008) .
However, the use of genetic testing for HBOC among high-risk individuals has been lower than expected, varying between 26% and 80% (Lerman, Croyle, Tercyak, & Hamann, 2002; Ropka, Wenzel, Phillips, Siadaty, & Philbrick, 2006) , in addition, a significant number of those who get tested do not seek their results (Pasacreta, 2003) . Although research examining how women decide whether to have genetic testing for HBOC is underway, there has been little attention to the level of decisional conflict they experience in making this life-altering decision. The purpose of this study was to bring attention to this significant topic by evaluating the psychometric properties of the Decisional Conflict Scale (DCS; O'Connor, 1995) , modified to reflect decisional conflict that is specific to genetic testing for HBOC.
Background
Decisional conflict is a condition of hesitation and doubt about a forthcoming decision. It is defined by several contributing characteristics (i.e., verbalization of uncertainty, fluctuation between choices, postponed decision making, stress, selfabsorption, and the questioning of one's own beliefs). Decisional conflict is influenced by insufficient information concerning alternative choices and their consequences, lack of decision-making skills, and exceeding demands by significant others (O'Connor, 1993) . Individuals with high levels of decisional conflict about the choice at hand will most likely delay making a decision. Ultimately, high decisional conflict compromises one's quality of life (Eastwood, Doering, Roper, & Hays, 2008) .
High decisional conflict has been associated with decreased intention to use genetic testing (Peterson et al., 2006) . The decision to use genetic testing for HBOC is also likely influenced by family characteristics (D'Agincourt-Canning, 2006; Marteau & Weinman, 2006) . Linkages between family processes, family relationships, and the decision to use genetic testing have been hypothesized (Peterson, 2005; Wilson et al., 2004) . Women usually take on the responsibility of making decisions about genetic testing (Metcalfe et al., 2007) and of sharing genetic information with family members (Speice, McDaniel, Rowley, & Loader, 2002) . Those who refused genetic testing for HBOC found it a more difficult decision to make and felt pressure from significant others (Claes et al., 2003) . Uninformative BRCA1/2 test results led to higher decisional conflict and poorer decisional outcomes among breast cancer survivors (Rini et al., 2009) .
Development of the DCS
The original DCS was developed and tested psychometrically by O'Connor (1995) with individuals who were making a decision on influenza immunizations and breast cancer screening. When it was developed, the DCS included three subscales derived from the decisional conflict construct, which were named Decision Uncertainty (three items), Factors Contributing to Uncertainty (nine items), and Perceived Efficacy in Decision Making (three items; Table 1 ). Initial psychometric testing of the DCS elicited a testYretest coefficient of .81 and reliability coefficients of .58 to .92 (O'Connor, 1995) .
The original DCS has been adapted widely to measure decisional conflict in patients deciding to have hormone replacement therapy, colorectal cancer screening, breast cancer treatment, and treatment of benign prostatic hypertrophy, hypertension, and atrial fibrillation and in patients with schizophrenia. It has been used also in a trial evaluating the efficacy of a decision aid for HBOC genetic testing (Green et al., 2004) and to measure decisional conflict about cancer risk management among breast cancer survivors who received an uninformative BRCA1/2 test result (Rini et al., 2009) . Table 2 presents information about the development and adaptation of the DCS to different populations. However, validity was not reevaluated for the adapted DCS and few studies reported reliability data. All studies used the scale relying on the initial psychometric testing and accepting its properties as initially reported. However, when a nonstandardized measure is changed for subsequent use, it is altered into a different measure and therefore warrants new testing of psychometric properties (Waltz, Strickland, & Lenz, 2010) . Thus, the purpose of this study was to evaluate the reliability and validity of the modified DCS for genetic testing for HBOC.
Methods

Data Collection Procedures
The scale was administered as part of a survey that examined individual and familial factors that influence decision making for HBOC (Katapodi et al., 2011) . Data for this cross-sectional cohort study were obtained from two genetic clinics affiliated with a comprehensive cancer center and a major research-intensive university. The clinics provide genetic risk assessment, counseling, and genetic testing to individuals at risk for hereditary cancer syndromes, including HBOC. The study recruited two cohorts of women: (a) women who had pursued genetic testing for HBOC q (probands) and (b) one of their female relatives (relative) who had not pursued testing, although she had a similar risk of carrying a genetic mutation. Participants were older than 18 years of age and completed the survey in English. Briefly, a genetic counselor identified eligible participants by analyzing pedigrees of women that had genetic testing for HBOC within the past 5 years prior to the initiation of the study. Eligible probands were sent an invitation letter, tailored to identify their high-risk relatives (e.g., sister, maternal or paternal aunt). After probands agreed to participate in the study, they were mailed a self-administered survey, along with an invitation letter for their high-risk relative. Relatives who agreed to participate were mailed a similar survey. Data collection occurred from January 2008 through April 2009. The institutional review board of the university and the protocol review committee of the cancer center approved the study.
Measures
Members of participating dyads (probandYrelative) were each mailed a 25-page, self-administered survey that captured demographic information, personal and family history of genetic testing and breast or ovarian cancer, perceived risk of HBOC, perceived utility of genetic testing (benefits minus barriers of genetic testing), knowledge about the genetics of HBOC, and decisional conflict about genetic testing for HBOC. Perceived risk was assessed with 19 items assessing absolute and comparative perceptions of risk of developing breast and ovarian cancer. These items were developed previously and validated with a sample including 15% of women at high risk for HBOC (Katapodi, Dodd, Lee, & Facione, 2009 ). Three additional items were developed for this study: ''How informed are you about your HBOC risk?'', ''How much do you know about HBOC?'', and ''How much control you feel you have over your HBOC q (2005) Pregnant women (n = 227) Cronbach's ! = .63 at 28 weeks and .67 at 36 weeks Laupacis et al. (2006) Cardiac patients (n = 120) None reported *Note. The only study that examined validity of the Decisional Conflict Scale was the original study by O'Connor (1995) .
risk?'' Perceived utility of genetic testing was assessed using seven items for perceived benefits of genetic testing and eight items for perceived barriers of genetic testing for HBOC (Jacobsen, Valdimarsdottir, Brown, & Offit, 1997) . A composite score from the two subscales creates a measure of perceived utility of genetic testing.
DCSYGenetic Testing HBOC
The items used in the DCSYGenetic Testing for HBOC were adapted from the original DCS (O'Connor, 1995) . All 16 items were scored on a 5-point Likert scale and were changed to a positive wording format so that a higher score would indicate higher decisional conflict. When participants were given the DCSYGenetic Testing HBOC, they were instructed to ''Think about the choice to have genetic testing for HBOC'' and then to check the box indicating their degree of agreement with each statement. Each box was grounded with the worded Likert response. The Likert scale was coded with 1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = strongly agree.
Procedures for Data Analyses
The suitability of the sample size was examined prior to analyses. Due to the small number of missing responses, it was determined a priori that those participants who had omitted questions on the DCSYGenetic Testing HBOC would be excluded from data analyses. This resulted in complete data from 342 participants. As a rule of thumb, Tabachnick and Fidell (2007) recommend having at least 300 cases for factor analysis. Nunnally and Bernstein (1994) suggested having 10 cases per item in the instrument for factor analysis. Thus, with 16 items in the DCSYGenetic Testing HBOC and 342 participants, an adequate sample size was achieved for factor analysis. Sampling adequacy for factor analysis was also determined using the KaiserYMeyerY Olkin and the Bartlett test. The KaiserYMeyerYOlkin measure of sampling adequacy was .93, indicating a ''marvelous'' sample for factor analysis (Kaiser, 1974, p. 35) . The Bartlett's Test of Sphericity was significant (c 2 = 6,444.17, p G .001), indicating that relationships among the items existed (Tabachnick & Fidell, 2007) . All data analyses were undertaken using SPSS Version 17.0. Factor analysis was applied to consolidate items and identify the factors within the DCSYGenetic Testing HBOC. The construct validity of the DCSYGenetic Testing HBOC was examined using principal axis factoring (PAF) with oblimin rotation. Additional correlational analyses were completed to ascertain the presence of contrast, convergent, divergent, and predictive validity of the revised measure.
Results
Participants
The sample consisted of 200 probands and 172 relatives. Only 342 participants completed all 16 items of the DCSY Genetic Testing HBOC. The mean age of the sample was 49.6 T 13.6 years, ranging from 18 to 81 years. Most participants (95.7%) reported having health insurance. The demographics of the sample are described in more detail in Table 3 . Overall, the sample included women who were primarily Caucasian, well educated, married or partnered, and of high socioeconomic status.
Interitem Correlations
The interitem correlations were assessed for the existence of conceptual redundancy. First, the correlation matrix was inspected for values that were lower than .30; none were identified. However, one value above .90 was noted. The items ''I feel I know the pros of each option'' and ''I feel I knew the cons of each option'' were correlated at .92. Factor analysis was run with both of these items included and then with each deleted. The decision was made to include both of these items because they examine the perceived risks and benefits of genetic testing, they improved factor structure, and they increase the applicability of the model to those who may have more or less favorable opinions about genetic testing for HBOC. scores and standard deviations of the 16 items prior to data analysis.
Reliability
The internal consistency of the DCSYGenetic Testing HBOC was evaluated. The reliability coefficient should be .80 or greater for an instrument that has previously been tested (Nunnally & Bernstein, 1994) . In this study, items were reworded to capture the content of genetic testing for HBOC and were restated in positively worded items. After these changes, the Cronbach's alpha coefficient for the DCSY Genetic Testing HBOC was .96, which is excellent for what is considered by Waltz et al. (2010) to be a new scale.
Validity
The types of validity used in assessing the DCSYGenetic Testing HBOC were face, construct, contrast, convergent, divergent, and predictive validity (Table 5 ).
Face Validity Face validity ''is not validity in the true sense and refers only to the appearance of the instrument to the layperson'' (Waltz et al., 2010, p. 166) . The DCSYGenetic Testing HBOC is an easy-to-read, well-spaced scale, has minimal wording, and is presented to the participant on one page. The reading level of the DCS was cited by O'Connor (1995) as being at an eighth grade level. The DCSYGenetic Testing HBOC has a Flesch-Kincaid reading level of 6, indicating that participants with a sixth grade education or higher would be able to read and complete the scale (Flesch, 1948; Kincaid, Fishburne, Robers, & Chissom, 1975) .
Construct Validity The 16 items in the DCSYGenetic Testing HBOC were examined with various exploratory factor analysis methods. Principal component analysis with varimax and oblimin rotation, PAF with varimax and oblimin rotation, maximum likelihood factor extraction, and unweighted least squares factoring were conducted to determine the best factor solution. Prior to beginning the factor analysis, values were preset for analysis. The criteria that determined the number of factors and the number of items within a factor have been outlined by Nunnally and Bernstein (1994) and include (a) the point of discontinuity of the scree plot, (b) an eigenvalue greater than 1, and (c) item factor loading greater than .40. After multiple iterations, PAF with oblimin rotation was determined to elicit the best factor solution. The three-factor solution that resulted from this exploratory factor analysis was consistent with the number of factors displayed in the scree plot and with factors having an eigenvalue of greater than 1. This analysis elicited three factors, named Lack of Knowledge About the Decision (seven items), Lack of Autonomy in Decision Making (six items), and Lack of Confidence in Decision Making (three items). The total variance of decisional conflict in the context of genetic testing for HBOC explained by the three factors was 81.57%. The reliabilities of the new subscales were assessed and were found to be satisfactory, with a range of .87Y.97 (Table 6 ). The pattern matrix and structure matrix (Pallant, 2007) are demonstrated in Table 7 . There were no items that loaded on more than one component at .40 or greater.
Although the DCSYGenetic Testing for HBOC includes the 16 items of the original DCS, two items loaded on a different factor. The two items are used to examine perceived pressure and perceived support from significant others in the decision to use genetic testing for HBOC. These two items loaded on the Lack of Autonomy in Decision Making factor, instead of Factors Contributing to Uncertainty of the original DCS (Table 7) . These new factor loadings demonstrate that the adapted DCSYGenetic Testing for HBOC includes one of the original subscales and two new subscales. This finding suggests that decisional conflict for genetic testing is markedly distinct from decisional conflict in other healthcare decisions.
Contrast Validity Contrast validity assesses the differences measured by an instrument between two or more diverse groups. Contrast validity was determined using an independent t test between the cohort of probands, who used genetic testing, and the cohort of female relatives, who did not. The hypothesis being tested was that there would be differences between the two groups on the decisional conflict they faced when considering genetic testing. As hypothesized, the t test revealed significant differences (p G .001) between the probands and their relatives on all factors (Lack q (Table 8) .
Convergent Validity Convergent validity is established through a significant correlation with another item or instrument that measures the same construct (Tabachnick & Fidell, 2007) . Convergent validity was tested using each factor independently and correlating it with items from the Perceived Risk Questionnaire used in the study. First, the correlation between the item inquiring ''How informed are you about your HBOC risk?'' and Factor 3, Lack of Confidence in Decision Making, was assessed. A significant negative correlation was found (r = j.31, p G .001), indicating that the more informed an individual feels, the higher his or her confidence in making decisions. Second, the correlation between the item inquiring ''How much do you know about HBOC?'' and Factor 1, Lack of Knowledge in Decision Making, was evaluated. A significant negative correlation was found (r = j.47, p G .001), indicating that knowledge about HBOC decreases perceived lack of knowledge in decision making. Finally, the correlation between the item inquiring ''How much control you feel you have over your HBOC risk?'' and Factor 2, Lack of Autonomy in Decision Making, was determined.
A small but significant negative correlation was found (r = j.13, p G .05), indicating that the more conflict individuals reported with autonomy, the less control they felt they had in decision making. These correlations are congruent with the theory of decision making and the construct q (Items 4, 5, 6, 7, 8, 9, and 12) 14.61 5.81 .97
Factor 2: Lack of Autonomy in Decision Making (Items 10, 11, 13, 14, 15, and 16) Genetic Testing 373 of decisional conflict. Insufficient information about the problem at hand and alternative options, lack of decisionmaking skills, and demands by significant others are factors contributing to increased decisional conflict (O'Connor, 1993) .
Divergent Validity An instrument's divergent validity is assessed by its low correlation with a scale or item that measures a different construct (Tabachnick & Fidell, 2007) . Divergent validity was tested using the total score of the DCSYGenetic Testing HBOC and an item from the Perceived Utility of Genetic Testing (PUGT) scale (Jacobsen et al., 1997) , which assesses an individual's view on the usefulness of genetic testing. An item from the PUGT scale asks whether ''genetic testing will ease my mind regardless of the test result,'' with a Likert score of 1 = strongly disagree to 5 = strongly agree. A significant negative correlation (r = j.30, p G .01) was found between the DCSYGenetic Testing HBOC total score and this item from the PUGT scale. Thus, decisional conflict is decreased by the belief that q genetic testing will ease an individual's mind, which is theoretically congruent with the construct of decisional conflict.
Predictive Validity Predictive validity is used to assess an instrument's ability to estimate some form of behavior (Nunnally & Bernstein, 1994) . The predictive validity of the DCSYGenetic Testing HBOC was evaluated with the instrument's ability to predict whether a woman would pursue prophylactic measures to reduce her HBOC risk. Significant correlations were found between the total score of the DCSYGenetic Testing HBOC and items inquiring whether women ''had a prophylactic mastectomy'' (r = .20, p G .001) and whether they ''had a prophylactic oophorectomy'' (r = .24, p G .001). These correlations indicate that women with higher decisional conflict who were considering prophylactic surgery as a means of reducing their HBOC risk were likely more ambivalent about the implications of the test result for their own health. Connor, two items loaded on a different factor. These two items examine perceived pressure and perceived support in the decision to pursue genetic testing. The different item loadings demonstrate that decisional conflict about genetic testing is inherently distinct from decisional conflict for decisions related to cancer screening and cancer treatment. The new factor loadings support hypotheses about intrafamilial decision-making processes that are paramount in the context of HBOC and reflect the hypothesized contextual dynamics that influence autonomy in decision making for genetic testing (Peterson, 2005; Wilson et al., 2004) .
Discussion
Limitations
One limitation of this study was the homogeneous sample. Participants were mostly Caucasian women of high educational and socioeconomic status; therefore, their decisional conflict may be different from that of women of other ethnicities, educational levels, and socioeconomic status. Genetic mutations that predispose to HBOC are more common among specific Caucasian subgroups (i.e., Ashkenazi Jewish, Icelandic, French-Canadian, Swedish, and Hungarian; ACS, 2011). Thus, although our sample was homogenous, it was representative of women who seek genetic testing in the two high-risk clinics, supporting the relevance of these results to the general population at high risk for HBOC. Nevertheless, future research should evaluate this scale in a more diverse group of women. A second limitation is that history of prophylactic surgery was based on self-report and may not be accurate. Finally, the retrospective and cross-sectional study design limited the ability to capture the dynamics of the decision-making process at the time that the actual decision for genetic testing was being made. Despite its limitations, the study included a large sample (n = 372) of women at various levels of risk for HBOC. Moreover, the recruitment method allowed for comparison of two related cohorts of women, namely probands who pursued genetic testing and their high-risk relatives who did not.
Clinical Implications
Attending to women's decisional conflict about genetic testing for HBOC should be a priority in clinical practice. Rini and colleagues (2009) reported that a substantial proportion of breast cancer survivors who received uninformative BRCA1/2 test results had high decisional conflict scores and were at risk for poor decisional outcomes. They also reported that the women who were considering riskreducing mastectomy or oophorectomy experienced higher decisional conflict than the women who did not consider these options. This is consistent with the positive correlations between DCSYGenetic Testing HBOC and uptake of prophylactic mastectomy and prophylactic oophorectomy reported in this study. Together, these findings have important clinical implications. Decisions for life-altering surgery, such as prophylactic mastectomy and oophorectomy, are difficult to make especially among asymptomatic women who are at high risk for HBOC. These women are likely to experience lingering dissatisfaction and lack of confidence in their decisions for HBOC genetic testing and risk management. This study made a contribution in this clinical area by evaluating the psychometric properties of the DCSYGenetic Testing for HBOC. The scale is an important tool for researchers and healthcare providers who are working with women trying to decide whether genetic testing is the right choice for them. The scale can identify women who experience high decisional conflict so they can receive more clinical attention and decisional support. q
